• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Cold Chain Packaging and Logistics

    How Artificial Intelligence and Machine Learning are Transforming the Life Sciences

    Challenges of Preparing Highly Potent Oral Products

    Bioprocessing Trends

    Sustainable Manufacturing
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    groninger Continues Growth in the US

    Catalent Bolsters Cell and Gene Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    What Does the Future of API Synthesis Look Like?

    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Jaguar Health Achieves Key Milestone for Crofelemer API Manufacturer
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Bolsters Cell and Gene Services

    CDMO Sirio Pharma Completes the Acquisition of Best Formulations

    Meeting the Container Closure Integrity Requirements in the Revised EU Annex 1

    Case Study: Secondary Sourcing Strategies to Ensure Supply Chain Security

    Beat the Supply Chain Backlog
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Catalent Bolsters Cell and Gene Services

    Crown Bioscience to Acquire Indivumed’s Service Biz and Supporting Biobank

    Stevanato Group, Transcoject Partner on Pre-Fillable Syringe Polymer Options
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Adare Partners with Veeva to Strengthen Quality Operations

    KBI Secures Swissmedic Regulatory Establishment License for Facility in Geneva

    Enhancing Ease of Use, Batch Turnaround, and Process Flexibility

    Understanding the Essential Role of a Qualified Person

    Altasciences Los Angeles Clinical Site Receives CAP Accreditation
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    Bachem

    BioIVT

    Quotient Sciences

    Chiron Recombinant Proteins
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    Bachem

    BioIVT

    Quotient Sciences

    Chiron Recombinant Proteins
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    India Report

    Indian Firms Ramp Up R&D

    Accelerating on research spend.

    Indian Firms Ramp Up R&D
    Related CONTENT
    • Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations
    • Highly Potent Expansions
    • High Containment & Cost Savings with Single Use Isolator Technology
    • API to ADC: A Journey Through High Potency
    • FDA Approves Boehringer’s Ofev
    S. Harachand, Contributing Editor10.15.19
    Research and development is back in the news in the Indian pharma sector after a protracted lull.

    Making a big splurge into the oncology segment, Lupin announced a licensing deal with Germany’s Boehringer Ingelheim in September to develop and commercialize one of the company’s lead MEK inhibitors.

    This class of drugs is currently approved for treating certain variants of melanoma in combination with other agents. Several MEK inhibitors are under clinical evaluation for their efficacy in different cancer types.

    Lupin’s MEK candidates have shown preclinical activity both as a single agent and in combination. In addition, they have demonstrated early clinical benefit in a small subset of patients, according to a company statement.

    The new partnership will see Lupin’s LN3794 clinically validated in combination with Boehringer’s innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

    The complementary mechanisms of action of KRAS inhibitors with MEK drugs results in increased anti-tumor activity keeping KRAS-driven cancers in check, based on preclinical data. According to Norbert Kraut, head of global cancer research at Boehringer Ingelheim, the drugs are expected to provide “more effective and durable responses for patients with cancers driven by activated KRAS who currently have limited treatment options available.”

    The deal will bring an upfront payment of $20 million to Lupin as well as potential additional payments for successful achievement of defined clinical, regulatory and commercial milestones for a total value of more than $700 million.

    Meanwhile, the deal entitles Boehringer with the global rights to commercialize the drug except in India. Lupin will receive double-digit royalties on the sales of the product.

    Last December, Lupin started a similar collaboration with U.S.-headquartered AbbVie to develop and commercialize its Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) inhibitors as novel treatments for hematological cancers. AbbVie licensed exclusive global rights to Lupin’s MALT1 inhibitor program. MALT1 protein is involved in the activation of T-cell and B-cell lymphocytes.

    Under the terms of the agreement, Lupin is eligible to receive total milestone payments of up to $947 million. The Mumbai-based firm has received an upfront payment of $30 million.

    The high-stakes discovery research gamble has never been a priority area for most of the Indian generic players. Of course, a few among them did venture out into the arena of discovery research with partial success.

    Interestingly, some of the leading players have suddenly wanted to accelerate their drug discovery efforts and started building a robust research pipeline, along the lines of Lupin.

    Sun Pharma’s recent tie-up with HitGen is a case in point. Sun Pharma Advanced Research Company (SPARC) entered into a pact with the Chinese biotech firm in March to pursue small molecule leads. HitGen uses a platform technology based on DNA-encoded library design, synthesis and screening to identify novel leads. The technique is found to be capable of yielding huge numbers of DNA-encoded molecules, with each compound screened against protein targets for strong binding properties.

    Diversity of compounds coupled with quick turnaround time and relatively lower costs makes HitGen’s DNA-encoded chemistry an attractive proposition to pharma companies.

    Under this collaboration, HitGen will discover novel leads for SPARC and receive upfront and milestone payments.

    Firms that do not have a direct stake in discovery research are now intensifying their pursuit in R&D, reports show.

    Aurobindo Pharma, for example, has decided to spend over 5 percent of its sales value on R&D for the current financial year 2019-20. The Hyderabad-based drug manufacturer, which raked in annual sales revenue of $2.6 billion in 2017-18, invested 4.5% of its turnover in R&D last fiscal. Aurobindo is planning to boost its biosimilar development program in addition to  formulations and API research.

    In a related development, AstraZeneca opened a development operations center in Bangalore to support clinical research in India. The center, which was opened in May, will support the development of AstraZeneca’s innovative medicines and host clinical trial experts focused on core therapeutic areas such as oncology, cardio-vascular, renal and metabolism, and respiratory, said a company release. The facility can handle 20 studies across 150 sites. 


    S. Harachand
    Contributing Editor

    S. Harachand is a pharmaceutical journalist based in Mumbai. He can be reached at harachand@gmail.com.
    Related Searches
    • API
    • abbvie
    • Development
    • discovery
    Suggested For You
    Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations
    Highly Potent Expansions Highly Potent Expansions
    High Containment & Cost Savings with Single Use Isolator Technology High Containment & Cost Savings with Single Use Isolator Technology
    API to ADC: A Journey Through High Potency API to ADC: A Journey Through High Potency
    FDA Approves Boehringer’s Ofev  FDA Approves Boehringer’s Ofev
    Boehringer Ingelheim, MD Anderson Form Virtual Cancer R&D Center Boehringer Ingelheim, MD Anderson Form Virtual Cancer R&D Center
    Alkahest Appoints Chief Business Officer Alkahest Appoints Chief Business Officer
    Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline
    Pricing Headwinds Pricing Headwinds
    Boehringer-Ingelheim Boehringer-Ingelheim
    Sanofi Sanofi
    Outsourcing in China: How far can it go? Outsourcing in China: How far can it go?
    11	Bristol-Myers Squibb 11 Bristol-Myers Squibb
    Boehringer, Yuhan Enter NASH Pact Boehringer, Yuhan Enter NASH Pact
    Oxford Bio Receives Boehringer Milestone Oxford Bio Receives Boehringer Milestone

    Related Features

    • cGMP Manufacture
      Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations

      Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations

      The benefits of leveraging a mix of GMP and pre-GMP facilities.
      Didier Combis, Commercial Director, Seqens CDMO 10.15.19

    • Cytotoxics and High Potency Manufacturing
      Highly Potent Expansions

      Highly Potent Expansions

      CDMOs see HPAPI demand rising
      S. Harachand, Contributing Editor 09.16.19

    • Cytotoxics and High Potency Manufacturing
      High Containment & Cost Savings with Single Use Isolator Technology

      High Containment & Cost Savings with Single Use Isolator Technology

      The trend towards HPAPIs is driving the need for innovative containment systems.
      Scott Patterson, Vice President Commercial Sales, ILC Dover 09.16.19


    • Cytotoxics and High Potency Manufacturing
      API to ADC: A Journey Through High Potency

      API to ADC: A Journey Through High Potency

      This class of compounds represents a major advance in oncology research and treatment application.
      Maurits Janssen, Head Commercial Development API, Lonza Pharma & Biotech 09.16.19

    • Breaking News | Drug Development | Trials & Filings
      FDA Approves Boehringer’s Ofev

      FDA Approves Boehringer’s Ofev

      Becomes the first and only therapy to slow the rate of decline in pulmonary function in systemic sclerosis-associated ILD
      09.09.19

    Loading, Please Wait..
    Trending
    • Sarepta And Catalent Expand Manufacturing Partnership
    • Forge Biologics Strengthens Genetic Medicine CDMO Capabilities
    • Colorcon Signs Agreement To Purchase Airnov Healthcare Packaging
    • The Ongoing Evolution And Implementation Of DCTs In 2023
    • EyePoint Pharmaceuticals To Build GMP Mfg. Facility In Northbridge, MA
    Breaking News
    • Pasithea Signs CMC Development and Manufacturing Agreement
    • Experic Expands Analytical Capabilities and Facilities
    • List Labs Expands Manufacturing Capacity
    • groninger Continues Growth in the US
    • Catalent Bolsters Cell and Gene Services
    View Breaking News >
    CURRENT ISSUE

    November/December 2022

    • Cold Chain Packaging and Logistics
    • Optimizing Supply Chains for Allogeneic Cell Therapy Trials
    • Sustainable Manufacturing
    • Bioprocessing Trends
    • How Artificial Intelligence and Machine Learning are Transforming the Life Sciences
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Probiotics Supplementation Reduces Complications in Colorectal Cancer Patients
    Vitamin D Supplementation Reduces Risk of Dynapenia
    Sustained-Release Caffeine Ingredient Offers Mood, Performance Benefits
    Coatings World

    Latest Breaking News From Coatings World

    Epoxytec Announces New Website Launch
    Paints and Coatings Market Worth $212B by 2026: MarketsandMarkets
    Axalta Releases Fourth Quarter and Full Year 2022 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BMP Medical Expands Sterling, Massachusetts Facility
    Abbott's Proclaim XR SCS OK'ed for Diabetic Neuropathy
    Environmental Sustainability Becoming Increasingly Important to Medtech Industry
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pasithea Signs CMC Development and Manufacturing Agreement
    Experic Expands Analytical Capabilities and Facilities
    List Labs Expands Manufacturing Capacity
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Haircare Brand Uncle Funky’s Daughter Announces Retail Expansion
    TRESemmé Introduces New Pro Infusion Collection
    Walgreens Boots Alliance Shares 2022 ESG Report
    Happi

    Latest Breaking News From Happi

    KimChi Beauty Launches Spinning Hearts Love 02 Ahead of Valentine’s Day
    Dark & Lovely Names Actress Meagan Good Brand Ambassador
    Natural Household Care Company Tru Earth Adds Dishwasher Detergent Tablets
    Ink World

    Latest Breaking News From Ink World

    Xerox Releases 4Q, Full-Year 2022 Results
    Electronics For Imaging Names Frank Pennisi as CEO
    Fiery to Separate from EFI, Remain Wholly-Owned by Siris
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    EFI appoints Frank Pennisi CEO, Fiery now an independent business
    Bobst boosts senior sales team with Keith Nagle
    Penmar Industries adds Screen Truepress Jet L350UV SAI digital press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Essity’s Sales Grow
    Thinx to Pay up to $5 million to Settle Class Action Suit
    Typar Highlighting New Building Innovations
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthofix Launches the Mariner Deformity System
    Tyber Medical Hires 2 New Execs
    Miach Ortho Raises $40M in Series B Funding
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Smart Devices with Privacy Focus Have More Consumer Appeal
    Siman Group Partners with SML to Unlock Full Retail Potential with RFID
    Brewer Science Presents Optics Integration Solutions at SPIE Photonics West

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login